Related Experiment Videos
Insights
Cerivastatin, a cholesterol-lowering drug, was withdrawn due to fatal rhabdomyolysis, particularly when combined with gemfibrozil. Safer lipid-lowering drug use is recommended to improve patient benefit and risk.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Cardiovascular Medicine
Context:
- Cerivastatin, a statin medication, was withdrawn globally.
- Reports linked cerivastatin, especially with gemfibrozil, to over 30 deaths in the US.
- Severe rhabdomyolysis was identified as the primary cause of mortality.
Purpose:
- To review the safety concerns associated with cerivastatin.
- To analyze the adverse events, including rhabdomyolysis, linked to cerivastatin.
- To provide recommendations for optimizing the benefit/risk ratio of lipid-lowering drug therapies.
Summary:
- Cerivastatin withdrawal followed reports of fatal rhabdomyolysis in patients, notably those using it with gemfibrozil.
- Cases of severe muscle breakdown were also observed in patients treated with cerivastatin alone.
- The fibrate gemfibrozil is no longer marketed in Belgium.
Impact:
- Highlights the critical importance of drug-drug interaction monitoring in lipid-lowering therapy.
- Underscores the need for pharmacovigilance to ensure patient safety.
- Informs clinical practice regarding the judicious use of statins and fibrates.
Abstract:
Cerivastatin was recently withdrawn from the market after the report of more than 30 deaths in the United-States among patients receiving a combination of cerivastatin and gemfibrozil, a fibrate which is not anymore on the Belgian market. The cause of death was attributed to severe rhabdomyolysis. Cases were also reported among patients treated by cerivastatin only. Recommendations for better use of lipid-lowering drugs are given in order to optimize the benefit/risk ratio of such treatment.